Invetis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-12-2024
- Paid Up Capital ₹ 1.00 M
as on 16-12-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -14.21%
(FY 2023)
- Profit 155.15%
(FY 2023)
- Ebitda -63.88%
(FY 2023)
- Net Worth 34.64%
(FY 2023)
- Total Assets -9.92%
(FY 2023)
About Invetis Lifesciences
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sathiskannan Sivalingam, Muthu Gopalan, Karthikeya Guruswamy, and Two other members serve as directors at the Company.
- CIN/LLPIN
U15122UP2014PTC065251
- Company No.
065251
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Invetis Lifesciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Perumal Kamalanathan  | Director | 04-Aug-2014 | Current |
| Sathiskannan Sivalingam | Director | 04-Aug-2014 | Current |
| Muthu Gopalan | Director | 04-Aug-2014 | Current |
| Karthikeya Guruswamy | Director | 04-Aug-2014 | Current |
| Nedunchezhian Ramasamy | Director | 30-Aug-2014 | Current |
Financial Performance and Corporate Structure Insights of Invetis Lifesciences.
Invetis Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.21% decrease. The company also saw a substantial improvement in profitability, with a 155.15% increase in profit. The company's net worth Soared by an impressive increase of 34.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Invetis Lifesciences?
Unlock access to Invetis Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Invetis Lifesciences?
Unlock and access historical data on people associated with Invetis Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Invetis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Invetis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
